Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Other Non-Current Assets (2019 - 2026)

Enliven Therapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Other Non-Current Assets at $1.2 million for Q1 2026, down 83.49% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (down 83.49% YoY), and the annual figure for FY2025 was $656000.0, down 90.86%.
  • Other Non-Current Assets reached $1.2 million in Q1 2026 per ELVN's latest filing, up from $656000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.6 million in Q2 2024 and bottomed at $54000.0 in Q1 2023.
  • Median Other Non-Current Assets over the past 5 years was $4.1 million (2023), compared with a mean of $3.6 million.
  • The largest annual shift saw Other Non-Current Assets soared 13903.7% in 2024 before it plummeted 90.86% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $175000.0 in 2022, then surged by 2237.71% to $4.1 million in 2023, then skyrocketed by 75.38% to $7.2 million in 2024, then tumbled by 90.86% to $656000.0 in 2025, then skyrocketed by 81.1% to $1.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for ELVN at $1.2 million in Q1 2026, $656000.0 in Q4 2025, and $7.1 million in Q3 2025.